Publications in collaboration with researchers from Clínica Universitaria de Navarra (89)

2024

  1. Access to melanoma drugs in Spain: a cross-sectional survey

    Clinical and Translational Oncology, Vol. 26, Núm. 10, pp. 2572-2583

  2. Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis

    Clinical and Translational Oncology

2023

  1. SARS-CoV-2 infection in patients with melanoma: results of the Spanish Melanoma Group registry

    Clinical and Translational Oncology, Vol. 25, Núm. 3, pp. 768-775

2020

  1. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

    Cancer Cell, Vol. 38, Núm. 4, pp. 500-515.e3

  2. Predicting circulating biomarker response and its impact on the survival of advanced melanoma patients treated with adjuvant therapy

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma

    Oncologist, Vol. 24, Núm. 10, pp. 1375-1383

2018

  1. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

    Annals of Oncology, Vol. 29, Núm. 10, pp. 2121-2128

  2. Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

    Therapeutic Advances in Medical Oncology, Vol. 10

2017

  1. Highlights of the season 2016-2017 by the Spanish Melanoma Group (GEM)

    Annals of Translational Medicine, Vol. 5, Núm. 19

  2. Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program

    Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 761-768

  3. Predictive factors of response to immunotherapy-a review from the Spanish Melanoma Group (GEM)

    Annals of Translational Medicine, Vol. 5, Núm. 19

  4. Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM)

    Annals of Translational Medicine, Vol. 5, Núm. 19

  5. Special issue on II translational meeting from the Spanish melanoma group

    Annals of Translational Medicine, Vol. 5, Núm. 19, pp. 1

2016

  1. Circulating melanoma exosomes as diagnostic and prognosis biomarkers

    Clinica Chimica Acta, Vol. 454, pp. 28-32

  2. Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach

    Clinical and Translational Oncology, Vol. 18, Núm. 10, pp. 1044-1050

  3. GRAY-B: An open label multicenter phase-2 GEM study on ipilimumab and radiation in patients with melanoma and brain metastases

    Annals of Oncology, Vol. 27, pp. vi383

  4. Pancreatic neuroendocrine tumors: Challenges in an underestimated disease

    Critical Reviews in Oncology/Hematology, Vol. 101, pp. 193-206

  5. Phase II multi-centre, non randomized, open label study of nivolumab in combination with ipilimumab as first line in adults patients with metastatic uveal melanoma. GEM 14-02

    Annals of Oncology, Vol. 27, pp. vi377

  6. Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: A retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study

    Melanoma Research, Vol. 26, Núm. 3, pp. 278-283

2015

  1. Assessment of EGFR and KRAS mutation status from FNAs and core-needle biopsies of non-small cell lung cancer

    Cancer Cytopathology, Vol. 123, Núm. 4, pp. 230-236